The contribution of metronidazole and two metabolites to the mutagenic activity detected in urine of treated humans and mice
- PMID: 318924
The contribution of metronidazole and two metabolites to the mutagenic activity detected in urine of treated humans and mice
Abstract
The urine of two patients receiving therapeutic doses of the trichomonacide, metronidazole, was analyzed for mutagenic activity using the histidine auxotroph TA1535 of Salmonella typhimurium. The activity detected in the urine was significantly higher than could be accounted for by the presence of the administered drug. Chromatographic analysis of the urine indicated the presence of the metabolite 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole, which when tested in vitro with TA1535 was found to be ten times more active than metronidazole. An additional urinary metabolite, 1-acetic acid-2-methyl-5-nitroimadazole, was found to be inactive when similarly tested. The in vitro mutagenic activity of metronidazole and the two metabolites was unchanged by the addition of phenobarbital- or Aroclor-induced rat liver homogenate to the test system. In addition, metronidazole and the hydroxymethyl metabolite reverted S. typhimurium TA100 but not TA1537, TA1538, or TA98, and the acetic acid metabolite failed to revert any of the tester strains. In studies with mice, metronidazole was required in excess of the human dose in order for significant amounts of the hydroxymethyl metabolite to be detected in the urine. Urine from mice pretreated with the hepatotoxin, carbon tetrachloride, prior to the administration of metronidazole demonstrated approximately a 50% reduction in mutagenic activity, and the formation of the urinary metabolites was inhibited. These findings indicate the production of metabolites from the parent compound by the liver of the intact animal which could not be determined by use of the standard in vitro liver homogenate system.
Similar articles
-
NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.Toxic Rep Ser. 1999 Aug;(59):1-66, A1-E7. Toxic Rep Ser. 1999. PMID: 11803702
-
NTP Technical Report on the comparative toxicity studies of allyl acetate (CAS No. 591-87-7), allyl alcohol (CAS No. 107-18-6) and acrolein (CAS No. 107-02-8) administered by gavage to F344/N rats and B6C3F1 mice.Toxic Rep Ser. 2006 Jul;(48):1-73, A1-H10. Toxic Rep Ser. 2006. PMID: 17160105
-
NTP Technical Report on the metabolism, toxicity and predicted carcinogenicity of diazoaminobenzene (CAS No. 136-35-6).Toxic Rep Ser. 2002 Sep;(73):1-23, A1-C6. Toxic Rep Ser. 2002. PMID: 12370695 Review.
-
Mutagenicity testing of the antiparasitic drug entizol (polfa) in the detection system of Salmonella typhimurium mutants.Mutat Res. 1980 Feb;77(2):117-26. Mutat Res. 1980. PMID: 6990236
-
Clinical pharmacokinetics of metronidazole.Clin Pharmacokinet. 1983 Jan-Feb;8(1):43-62. doi: 10.2165/00003088-198308010-00003. Clin Pharmacokinet. 1983. PMID: 6340904 Review. No abstract available.
Cited by
-
Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by "amitochondriate" protozoan parasites.Clin Microbiol Rev. 2007 Jan;20(1):164-87. doi: 10.1128/CMR.00019-06. Clin Microbiol Rev. 2007. PMID: 17223627 Free PMC article. Review.
-
Antimicrobial Transformation Products in the Aquatic Environment: Global Occurrence, Ecotoxicological Risks, and Potential of Antibiotic Resistance.Environ Sci Technol. 2023 Jul 4;57(26):9474-9494. doi: 10.1021/acs.est.2c09854. Epub 2023 Jun 19. Environ Sci Technol. 2023. PMID: 37335844 Free PMC article. Review.
-
Solid phase synthesis of a metronidazole oligonucleotide conjugate.Molecules. 2006 Jun 23;11(6):486-95. doi: 10.3390/11060486. Molecules. 2006. PMID: 17962782 Free PMC article.
-
In vitro efficacy of curcumin on Trichomonas vaginalis.Wien Klin Wochenschr. 2014 Apr;126 Suppl 1:S32-6. doi: 10.1007/s00508-014-0522-8. Epub 2014 Mar 12. Wien Klin Wochenschr. 2014. PMID: 24619489
-
Recombinant α-actinin subunit antigens of Trichomonas vaginalis as potential vaccine candidates in protecting against trichomoniasis.Parasit Vectors. 2017 Feb 16;10(1):83. doi: 10.1186/s13071-017-2009-8. Parasit Vectors. 2017. PMID: 28209207 Free PMC article.